Destiny Pharma announced the publication of new data in the journal Infection & Drug Resistance from a study evaluating the potency of Destiny Pharma's antibacterial drug, XF-73, against methicillin-resistant Staphylococcus aureus (MRSA) in two, industry-standard, skin infection models and comparing its efficacy against mupirocin, a leading topical antibiotic. The publication, entitled, "Efficacy of a Novel Antibacterial Agent Exeporfinium Chloride, (XF-73), against Antibiotic-Resistant Bacteria in Superficial Skin Infection Models" concluded that: XF-73 dermal formulation was 100 times more effective at killing MRSA (USA 300 strain) than the topical antibiotic mupirocin, in two skin infection models o Single doses of XF-73 and mupirocin reduced MRSA infection by >3 log 10 CFU/mL (p<0.0001) and <1 log 10, (p<0.05) respectively, relative to control (no treatment). XF-73 had significantly greater statistical efficacy than mupirocin in both MRSA skin infection models, (p<0.0001).

Mupirocin had little or no impact on mupirocin resistant-MRSA strains in the skin infection model, even following 2 doses, whereas XF-73's potency was not impaired and was equally effective against the mupirocin-resistant MRSA strains, maintaining a >3 log 10 reduction of this superbug. XF-73 further demonstrated its potency by achieving these results at a concentration of 0.2% (w,w), compared to 2% (w,w) marketed mupirocin ointment i.e. at 10 times less relative concentration.